Insmed Incorporated (NASDAQ:INSM)’s share price fell 5.9% on Tuesday . The company traded as low as $25.43 and last traded at $26.41. 2,018,005 shares traded hands during trading, an increase of 123% from the average session volume of 903,841 shares. The stock had previously closed at $28.07.
A number of brokerages have weighed in on INSM. Zacks Investment Research downgraded Insmed from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. HC Wainwright reissued a “buy” rating and set a $52.00 price target (up previously from $43.00) on shares of Insmed in a research report on Tuesday, April 9th. BidaskClub raised Insmed from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. Canaccord Genuity set a $44.00 price target on Insmed and gave the stock a “buy” rating in a research report on Friday, March 8th. Finally, ValuEngine raised Insmed from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 19th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $37.88.
The firm has a market capitalization of $2.02 billion, a PE ratio of -6.33 and a beta of 2.98. The company has a debt-to-equity ratio of 2.48, a current ratio of 4.82 and a quick ratio of 4.69.
Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.02). The firm had revenue of $21.90 million during the quarter, compared to the consensus estimate of $19.61 million. On average, equities analysts forecast that Insmed Incorporated will post -3.7 earnings per share for the current fiscal year.
In other news, Director Donald J. Hayden, Jr. sold 6,286 shares of the business’s stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $32.99, for a total transaction of $207,375.14. Following the completion of the sale, the director now owns 68,483 shares in the company, valued at $2,259,254.17. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Alfred Altomari sold 5,500 shares of the business’s stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $30.00, for a total value of $165,000.00. Following the sale, the director now owns 25,942 shares of the company’s stock, valued at approximately $778,260. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,686 shares of company stock valued at $790,767. Corporate insiders own 4.95% of the company’s stock.
Large investors have recently modified their holdings of the company. Raymond James & Associates boosted its holdings in shares of Insmed by 101.9% during the fourth quarter. Raymond James & Associates now owns 57,757 shares of the biopharmaceutical company’s stock worth $758,000 after acquiring an additional 29,150 shares during the period. Virtus ETF Advisers LLC boosted its stake in shares of Insmed by 23.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 20,606 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 3,855 shares during the period. Foresite Capital Management IV LLC boosted its stake in shares of Insmed by 9.8% in the fourth quarter. Foresite Capital Management IV LLC now owns 1,977,236 shares of the biopharmaceutical company’s stock valued at $25,941,000 after buying an additional 176,649 shares during the period. SG Americas Securities LLC bought a new stake in shares of Insmed in the fourth quarter valued at approximately $221,000. Finally, Bellevue Group AG boosted its stake in shares of Insmed by 42.9% in the fourth quarter. Bellevue Group AG now owns 809,146 shares of the biopharmaceutical company’s stock valued at $10,616,000 after buying an additional 242,845 shares during the period.
TRADEMARK VIOLATION NOTICE: This article was first published by Highlight Press and is owned by of Highlight Press. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://highlightpress.com/2019/05/21/insmed-insm-shares-down-5-9.html.
Insmed Company Profile (NASDAQ:INSM)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Further Reading: What is cost of equity?
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.